Stocks
Alnylam Pharmaceuticals Financial Statements (ALNY) |
||||||||||
| Alnylam Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 13.02.2020 | 11.02.2021 | 10.02.2022 | 23.02.2023 | 15.02.2024 | 31.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 219.8 | 492.9 | 844.3 | 1 037 | 1 828 | 2 014 | |||
| Operating Income, bln rub | -939.4 | -828.4 | -708.7 | -785.1 | -282.2 | -188.1 | ||||
| EBITDA, bln rub | ? | -939.4 | -771.1 | -709.1 | -894.4 | -228.1 | -146.1 | |||
| Net profit, bln rub | ? | -886.1 | -858.3 | -852.8 | -1 131 | -440.2 | -332.3 | |||
| OCF, bln rub | ? | -278.4 | -615.0 | -641.7 | -541.3 | 104.2 | 56.6 | |||
| CAPEX, bln rub | ? | 140.2 | 70.4 | 76.4 | 72.1 | 62.2 | 40.5 | |||
| FCF, bln rub | ? | -418.6 | -685.3 | -718.1 | -613.3 | 41.9 | 16.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 1 134 | 1 243 | 1 413 | 1 654 | 1 800 | 2 058 | ||||
| Cost of production, bln rub | 25.1 | 78.1 | 140.1 | 168.8 | 310.4 | 224.4 | ||||
| R&D, bln rub | 655.1 | 654.8 | 792.2 | 883.0 | 1 004 | 1 098 | ||||
| Interest expenses, bln rub | 0.000 | 84.5 | 143.0 | 156.0 | 121.2 | 134.2 | ||||
| Assets, bln rub | 2 395 | 3 407 | 3 643 | 3 546 | 3 830 | 4 205 | ||||
| Net Assets, bln rub | ? | 1 439 | 1 016 | 588.2 | -158.2 | -220.6 | 32.4 | |||
| Debt, bln rub | 303.8 | 521.2 | 997.6 | 1 320 | 2 683 | 1 302 | ||||
| Cash, bln rub | 1 536 | 1 874 | 2 436 | 2 192 | 2 439 | 2 772 | ||||
| Net debt, bln rub | -1 232 | -1 353 | -1 438 | -872.2 | 243.2 | -1 470 | ||||
| Ordinary share price, rub | 115.2 | 130.0 | 169.6 | 237.7 | 191.4 | 161.5 | ||||
| Number of ordinary shares, mln | 109.3 | 115.0 | 118.5 | 121.7 | 124.9 | 128.6 | ||||
| Market cap, bln rub | 12 584 | 14 945 | 20 087 | 28 919 | 23 908 | 20 772 | ||||
| EV, bln rub | ? | 11 352 | 13 592 | 18 649 | 28 047 | 24 152 | 19 302 | |||
| Book value, bln rub | 1 439 | 1 016 | 588 | -423 | -918 | 32 | ||||
| EPS, rub | ? | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.58 | |||
| FCF/share, rub | -3.83 | -5.96 | -6.06 | -5.04 | 0.34 | 0.12 | ||||
| BV/share, rub | 13.2 | 8.84 | 4.97 | -3.47 | -7.35 | 0.25 | ||||
| EBITDA margin, % | ? | -427.5% | -156.5% | -84.0% | -86.2% | -12.5% | -7.26% | |||
| Net margin, % | ? | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -16.5% | |||
| FCF yield, % | ? | -3.33% | -4.59% | -3.57% | -2.12% | 0.18% | 0.08% | |||
| ROE, % | ? | -61.6% | -84.5% | -145.0% | 714.9% | 199.5% | -1 027% | |||
| ROA, % | ? | -37.0% | -25.2% | -23.4% | -31.9% | -11.5% | -7.90% | |||
| P/E | ? | -14.2 | -17.4 | -23.6 | -25.6 | -54.3 | -62.5 | |||
| P/FCF | -30.1 | -21.8 | -28.0 | -47.2 | 570.0 | 1 293 | ||||
| P/S | ? | 57.3 | 30.3 | 23.8 | 27.9 | 13.1 | 10.3 | |||
| P/BV | ? | 8.75 | 14.7 | 34.1 | -68.4 | -26.0 | 642.0 | |||
| EV/EBITDA | ? | -12.1 | -17.6 | -26.3 | -31.4 | -105.9 | -132.1 | |||
| Debt/EBITDA | 1.31 | 1.75 | 2.03 | 0.98 | -1.07 | 10.1 | ||||
| R&D/CAPEX, % | 467.4% | 930.7% | 1 037% | 1 225% | 1 615% | 2 712% | ||||
| CAPEX/Revenue, % | 63.8% | 14.3% | 9.05% | 6.95% | 3.40% | 2.01% | ||||
| Alnylam Pharmaceuticals shareholders | ||||||||||
